

Prior dengue immunity enhances Zika virus infection of the maternal-fetal interface in rhesus macaques

C. M. Crooks¹, A. M. Weiler², S. L. Rybarczyk^{2,†}, M. I. Bliss², A. S. Jaeger³, M. E. Murphy^{4,‡}, H. A. Simmons², A. Mejia², M. K. Fritsch⁵, J. M. Hayes², J. C. Eickhoff⁶, A. M. Mitzey⁴, E. Razo⁷, K. M. Braun¹, E. A. Brown¹, K. Yamamoto^{5,§}, P. M. Shepherd⁵, A. Possell², K. Weaver², K. M. Antony⁸, T. K. Morgan^{9,10}, C. M. Newman⁵, D. M. Dudley⁵, N. Schultz-Darken², E. Peterson², L. C. Katzelnick^{11,||}, A. Balmaseda¹², E. Harris¹¹, D. H. O'Connor^{2,5}, E. L. Mohr⁷, T. G. Golos^{2,4,8}, T. C. Friedrich^{1,2*}, and M. T. Aliota^{3*}

¹Department of Pathobiological Sciences, University of Wisconsin-Madison, Madison, WI, USA

²Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI, USA

³Department of Veterinary and Biomedical Sciences, University of Minnesota, Twin Cities, St. Paul, MN, USA

⁴Department of Comparative Biosciences, University of Wisconsin-Madison, Madison, WI, USA

⁵Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI, USA

⁶Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, WI, USA

⁷Department of Pediatrics, University of Wisconsin-Madison, Madison, WI, USA

⁸Department of Obstetrics and Gynecology, University of Wisconsin-Madison, Madison, WI, USA

⁹Department of Pathology, Oregon Health and Science University, Portland, OR, USA

¹⁰Department of Obstetrics and Gynecology, Oregon Health and Science University, Portland, OR, USA

¹¹Division of Infectious Diseases and Vaccinology, University of California Berkeley, Berkeley, CA, USA

¹²Sustainable Sciences Institute, Managua, Nicaragua

*Corresponding author, T.C. Friedrich, Email: tfriedri@wisc.edu

*Corresponding author, M.T. Aliota, Email: mtaliota@umn.edu

† Present address, Sierra L. Rybarczyk, Sangamo Therapeutics, Richmond, CA, USA

‡ Present address, Megan E. Murphy, HIV Prevention Department, Terros Health, Phoenix, AZ, USA

§ Present address, Keisuke Yamamoto, Touro College of Osteopathic Medicine, New York, NY, USA

|| Present address, Leah Katzelnick, National Institute of Allergy and Infectious Disease, Bethesda, MD, USA

ABSTRACT

Concerns have arisen that pre-existing immunity to dengue virus (DENV) could enhance Zika virus (ZIKV) disease, due to the homology between ZIKV and DENV and the observation of antibody-dependent enhancement (ADE) among DENV serotypes. To date, no study has examined the impact of pre-existing DENV immunity on ZIKV pathogenesis during pregnancy in a translational non-human primate model. Here we show that prior DENV-2 exposure enhanced ZIKV infection of maternal-fetal interface tissues in macaques. However, pre-existing DENV immunity had no detectable impact on ZIKV replication kinetics in maternal plasma, and all pregnancies progressed to term without adverse outcomes or gross fetal abnormalities detectable at delivery. Understanding the risks of ADE to pregnant women worldwide is critical as vaccines against DENV and ZIKV are developed and licensed and as DENV and ZIKV continue to circulate.

55 INTRODUCTION

56 Pre-existing immunity to one DENV serotype can enhance the severity of a secondary
57 heterologous DENV infection, a phenomenon known as antibody-dependent enhancement
58 (ADE) (1–3). ZIKV is genetically and antigenically closely related to DENV, raising the
59 possibility that pre-existing DENV-specific antibodies might also modulate the severity of
60 ZIKV infection. ADE is thought to occur when antibodies from a prior DENV infection bind to
61 DENV virions and enhance uptake into Fcγ-receptor bearing cells rather than neutralizing
62 viral infectivity. This can lead to increased viral replication, a more robust inflammatory
63 response, and more severe disease (1, 4, 5).

64
65 Since the ZIKV outbreak in the Americas in 2015-2016, the potential role of DENV
66 antibodies in ZIKV infection has been examined in a variety of *in vitro*, *in vivo*, and
67 epidemiological studies. Studies in cell culture (6–13, 13–16) and immunocompromised
68 mice (6, 7, 13, 17–19) have found a range of outcomes from enhancement of, to protection
69 against, ZIKV infection. Data from non-human primates (NHP) and human cohorts support
70 the growing consensus that prior DENV infection does not enhance ZIKV infection in non-
71 pregnant individuals (20–29). However, DENV seroprevalence has been high in regions such
72 as French Polynesia (>80%), Yap, and New Caledonia that subsequently experienced large-
73 scale ZIKV outbreaks, suggesting that high DENV seroprevalence does not protect against
74 ZIKV outbreaks in a population (30–33).

75
76 The impact of prior DENV immunity on ZIKV pathogenesis during pregnancy remains
77 unclear. Studies in placental macrophages (34), human placental explants (34–36), and both
78 immunocompetent and immunocompromised pregnant mice (36, 37) have all demonstrated
79 enhancement of ZIKV infection in the presence of DENV antibodies. Retrospective studies
80 of pregnant women in South America did not identify an association between DENV
81 antibodies and adverse fetal outcomes (38–40); however, a majority of women in these
82 studies (>80%) had a prior DENV exposure, and outcomes could not be stratified by pre-
83 existing anti-DENV titer. A retrospective study of microcephaly cases in Brazil indicated that
84 there was reduced risk of microcephaly in areas with a DENV epidemic in the 6 years prior,
85 but an increased risk of microcephaly in areas with a DENV epidemic >7 years prior,
86 suggesting that the role of DENV-specific antibodies in modulating risk of congenital Zika
87 syndrome (CZS) might change as antibody titers wane with time (41). Understanding the
88 potential impact of DENV immunity on ZIKV outcomes in pregnant women is critical, as
89 vaccines against DENV and ZIKV are being developed, licensed, and distributed (42–44).
90 The rollout of Dengvaxia offers a cautionary tale, as vaccine-induced immunity led to more
91 severe disease outcomes in seronegative individuals (45). If ZIKV acts functionally as a fifth
92 serotype of DENV, then one would expect that this vaccine would also enhance Zika
93 disease by the same mechanism. Therefore, understanding whether the severity of maternal
94 and fetal ZIKV infection increases in pregnant, DENV-immune individuals should be a public
95 health priority.

96

NHP development and placentation resemble those of humans more closely than these processes do in other animal models, making NHPs particularly relevant to understanding viral infections in pregnancy (46). Here we apply our established NHP model (47) to assess the impact of DENV immunity on ZIKV pathogenesis in pregnancy. We do not detect a role for DENV immunity in modulating fetal outcomes in ZIKV-infected pregnant macaques. However, previous exposure to DENV did appear to increase ZIKV infection in tissues of the maternal-fetal interface, a result that warrants further examination.




Fig. 1. Experimental Overview. A cohort of eight non-pregnant macaques were challenged with 10⁴ PFU DENV-2 (orange). Approximately 1-3 months following DENV challenge, the eight DENV exposed macaques were bred, became pregnant, and were challenged with 10⁴ PFU ZIKV-PRVABC59, an Asian-lineage ZIKV isolate, on gestational day 45. A cohort of four pregnant, DENV-naïve macaques (blue) were challenged with ZIKV-PRVABC59 on gestational day 45. A control cohort of four macaques (green) were mock-challenged with PBS on gestational day 45. All three cohorts underwent the same experimental protocols for blood collection and sedation for ultrasound. At approximately gestational day 160, infants were delivered via cesarean section, and a set of maternal-fetal interface tissues with maternal biopsies were collected. Infants were placed with their mothers for long-term behavioral analysis, data from which is part of a separate study.

RESULTS

Prior DENV immunity does not modulate ZIKV replication kinetics in plasma

To characterize the range of pathogenic outcomes of congenital ZIKV infection in DENV-immune animals, we subcutaneously (s.c.) inoculated a cohort of eight non-pregnant, Indian-origin rhesus macaques with 10⁴ PFU of DENV-2/US/BID-V594/2006, a low-passage human isolate from Puerto Rico (Fig. 1). All eight macaques were productively infected with DENV-2, with peak plasma viral loads ranging from 10⁵-10⁷ vRNA copies/mL occurring on days 2-3 post-infection (Fig. 2). Following a biphasic decline in viral loads, all macaques cleared infection by day 11 post-infection.




Fig. 2. Replication of DENV-2. Eight non-pregnant macaques were challenged with 10^4 PFU DENV-2/US/BID-V594/2006, a 2006 human isolate from Puerto Rico. QRT-PCR was performed on plasma samples from 0-10, 14, 21, and 28 days post-infection. All values above the limit of quantification for the QRT-PCR assay (100 copies vRNA/mL plasma) are shown.

Macaques were bred 1-3 months following DENV inoculation. Once they became pregnant, the animals were challenged with 10^4 PFU of ZIKV-PRVABC59 (ZIKV-PR), a human isolate from Puerto Rico, on gestational day 45 (late first trimester). ZIKV challenge was 84-119 days following DENV inoculation in each case. This cohort of eight DENV-immune macaques was compared to a cohort of four pregnant, DENV-naïve macaques that were inoculated with ZIKV-PR at gestational day 45 and a cohort of four pregnant, DENV-naïve macaques mock-challenged with phosphate-buffered saline (PBS) at gestational day 45. Following challenge, all three cohorts (DENV-immune, DENV-naïve, and mock) underwent the same blood sampling and fetal monitoring protocols (Fig. 1). All macaques inoculated with ZIKV were productively infected. Peak plasma viremia occurred on days 2-4 post-infection, with titers ranging from 10^4 - 10^5 vRNA copies/mL in DENV-immune animals and 10^3 - 10^5 vRNA copies/mL in DENV-naïve animals (Fig. 3A, 3B). An unpaired t-test did not reveal significant differences between cohorts in the peak, area under the curve, or duration of viremia (Fig. 3C). Since prolonged ZIKV viremia >21 days is only observed in pregnancy, we assessed differences in duration both as a continuous variable and as a binary with viremia greater than or less than 21 days. This suggests that prior DENV-2 immunity did not alter ZIKV replication kinetics during gestation.




Fig. 3. ZIKV replication kinetics. Eight DENV-immune (A, orange) and four DENV-naïve (B, blue) macaques were challenged with 10^4 PFU of ZIKV-PRVABC59 at gestation day 45, which is late in the first trimester. Viral loads were assessed from plasma samples with ZIKV-specific QRT-PCR. All values above the limit of quantification (100 copies vRNA, mL plasma) are shown above. C. Graphs of the values for the peak, duration, and area under the curve of viremia for both DENV-immune and DENV-naïve macaques. An unpaired t-test was used for statistical comparison; ns = not significant ($p > 0.05$). Only values above the limit of quantification were used in statistical analyses.

DENV-immune macaques have low levels of ZIKV cross-reactive antibodies present at the time of challenge

For DENV-1-4, specific antibody titer ranges have been shown to enhance viral replication. As measured by a DENV inhibition ELISA (iELISA) assay, an intermediate antibody titer range of 1:21-1:80 was associated with a greater risk of developing severe dengue disease upon secondary exposure in a human cohort study (2). In a separate human cohort study, a plaque reduction neutralization test (PRNT50) titer of $<1:100$ was associated with an increased risk of severe DENV disease upon secondary exposure (48). In order to assess how cross-reactive DENV antibodies impact ZIKV outcomes during pregnancy, we characterized DENV and ZIKV antibody dynamics throughout the experimental time course.

We collected serum samples from macaques at 28 days post-DENV challenge, the day of ZIKV challenge, 28-35 days post-ZIKV challenge, and the day of c-section for measuring antibody responses to DENV and ZIKV. We used PRNT and iELISA to measure neutralizing antibodies or binding antibodies, respectively. In the PRNT, serial dilutions of serum antibodies are incubated with DENV or ZIKV, plated on a confluent monolayer of cells, and assessed for the dilution of antibodies required to reduce plaques by 50 or 90 percent (Supplementary Fig. 1). In iELISA, serum is serially diluted with peroxidase-conjugated DENV- or ZIKV-specific antibodies, which compete for binding to either an equal mixture of DENV1-4 antigens or ZIKV antigen (2, 49). Due to the impact of COVID-19, only 4 of 8 DENV-immune macaques were assayed via iELISA.

At 28 days post-DENV challenge, all eight macaques seroconverted and developed a robust antibody response to DENV-2 as measured by both DENV PRNT and DENV iELISA (Fig. 4A, 4C, 4D). At this time point, all macaques also showed a cross-reactive antibody response to ZIKV in one or both assays (3 of 4 macaques by iELISA and 7 of 8 macaques by PRNT), although generally below levels considered to be protective against subsequent ZIKV challenge (Fig. 4B, 4E, 4F)(50).

At the time of the ZIKV challenge, which fell 84-119 days after primary DENV infection, the DENV iELISA titers had increased four-fold in 6 of the 8 DENV-exposed macaques by PRNT and 4 of 4 macaques by iELISA (Fig. 4G, 4I, 4J). The cross-reactive ZIKV antibody titers remained stable or increased only modestly via ZIKV iELISA assay and PRNT (Fig. 4H, 4K, 4L) in the majority of macaques. However, cross-reactive ZIKV antibodies became undetectable by PRNT in 3 of 4 macaques that previously showed cross-reactivity at 28 days post-DENV challenge (Fig. 4K, 4L). By using both assays, we detected low levels of cross-reactive antibodies to ZIKV at the time of ZIKV challenge in all DENV-immune macaques; 2 of 4 macaques had ZIKV iELISA titers that fell within the range 1:21-1:80, which has previously been shown to increase risk of more severe DENV disease in humans. At the time of ZIKV challenge, no antibody responses to either ZIKV or DENV were detected using either assay in the DENV-naïve macaques (Fig. 4G, 4H, 4K, 4L).

Between 28-35 days post-ZIKV challenge, DENV antibody titers increased approximately four-fold following ZIKV challenge in DENV-immune macaques, as assessed by both DENV iELISA and PRNT (Fig. 4M, 4O, 4P). DENV titers in DENV-naïve macaques were only assessed via DENV iELISA, which revealed essentially no evidence of cross-reactive DENV antibodies, with a low-level antibody titer (1:11) to DENV in only 1 of 4 macaques (Fig. 4M). By 28-35 days post-ZIKV challenge, both DENV-immune and DENV-naïve macaques developed robust ZIKV-specific responses as measured by both ZIKV iELISA and PRNT (Fig. 4N, 4Q, 4R). Macaques in both cohorts that had viremia for a duration of >21 days (042-101, 042-103, 042-104, 044-101) developed antibody titers more than four-fold higher than those animals that had viremia for a duration of <21 days (042-102, 044-102, 044-103, 044-104) as determined by ZIKV iELISA. PRNT₅₀ titers were significantly higher ($p=0.0095$)

in DENV-immune macaques than DENV-naïve animals 28-35 days after ZIKV challenge, but no significant differences were noted in PRNT90 titers between groups. Together, these data provide evidence that antibodies capable of cross-reacting with ZIKV were present at the time of ZIKV challenge in DENV immune animals and show that all animals, regardless of DENV exposure history, develop a robust antibody response to ZIKV.




Fig. 4. DENV and ZIKV antibody dynamics. iELISA titers against DENV and ZIKV 28 days post-DENV challenge (A-F), the day of ZIKV challenge (G-L), 28-35 days post ZIKV challenge (M-Q), and the day of delivery (S-T). iELISA titers from DENV-immune animals shown in orange and from DENV-naïve animals shown in blue. Samples labeled “ND” were not detected. Using an unpaired t-test, PRNT50, but not PRNT90, titers from the DENV-immune group were significantly higher than the PRNT50 titer of DENV-naïve animals at 28 days post-ZIKV-challenge (** $p < 0.01$). Neutralization curves can be found in Supplementary Fig. 1.

No evidence of fetal growth restriction during gestation

To further characterize pathogenic outcomes during pregnancy, we define fetal health and growth parameters throughout gestation. No gross abnormalities, such as microcephaly, missing limbs, or hydrops fetalis were noted in any animals during gestation. Head circumference and biparietal diameter measurements were used to assess head size; femur length and abdominal circumference were used to assess overall fetal growth. Fetal measurements were compared to previously collected normative data on fetal growth trajectories in 55 pregnant rhesus macaques (51, 52). A z-score (number of standard deviations from the normative data) was calculated for each measurement at each timepoint. To account for animal-specific differences, z-scores were plotted as the change from the baseline measurement (open circles, Fig. 5). Overall group growth trajectories were calculated (solid line, Fig. 5) and used for statistical comparisons. Only the biparietal diameter of the mock-infected cohort was significantly lower than the normative data ($p = 0.01713$). There were no significant differences noted in pairwise comparisons of growth trajectories between groups. Taken together, these extensive fetal growth measurements suggest that there was no significant reduction in fetal growth in ZIKV-exposed macaques, regardless of their DENV immune history.

No evidence of vertical transmission in either DENV-immune or DENV-naïve macaques

At approximately gestational day 160 (term = gestational day 165), infants were delivered via cesarean section. During the surgery, a biopsy of the maternal mesenteric lymph node was taken to look for ZIKV vRNA in the dam. None of the mesenteric lymph node biopsies were positive in the DENV-immune cohort and only one of four mesenteric lymph node biopsies was positive in the DENV-naïve cohort, a difference which was not significant (Supplementary Table 1). Fetal tissues are not available for virological analysis because infants were placed with their mothers for long-term behavioral analysis, data from which will be part of a forthcoming study. We collected fetal plasma, umbilical cord plasma, and amniotic fluid; none of the fluid samples from infants in either cohort tested positive for ZIKV vRNA (Supplementary Table 1). There was no robust evidence to support direct infection of the fetus in either cohort, although the possibility of vertical transmission with viral clearance by the time of delivery cannot be ruled out.




Fig. 5. Fetal Growth. Comprehensive ultrasounds were performed weekly throughout gestation to monitor fetal health and perform four measurements of fetal growth: biparietal diameter and head circumference to evaluate head size; abdominal circumference and femur length to evaluate overall fetal growth. Using normative data from the California National Primate Research Center, a z-score was calculated for each measurement and the change in z-score from baseline is plotted for each measurement with an open circle. The overall growth trajectory for each group was quantified by calculating the regression slope parameters from baseline (solid line). When compared to the normative data, mock-infected animals had significantly reduced biparietal diameter growth ($p=0.01713$). No other significant differences were detected in comparisons to the normative data or in comparisons between the experimental groups.

Enhanced infection of the maternal-fetal interface in DENV-immune macaques

We performed an extensive dissection of both discs of the placenta in order to understand the distribution of ZIKV in placental tissues. Positive tissue samples were detected above the theoretical limit of detection of our QRT-PCR assay in 5 of 8 DENV-immune macaques and only 1 of 4 DENV-naïve macaques (Fig. 6A). Using a Mann-Whitney U test, there was a significantly higher burden of ZIKV RNA in the chorionic plate in the DENV-immune group as compared to the DENV-naïve group ($p<0.01$). Although there was a trend toward a greater burden of ZIKV in the fetal membranes in DENV-immune macaques, there were no statistically significant differences between cohorts in vRNA burden in the other MFI tissues (decidua, chorionic villi, umbilical cord, fetal membranes, and uterine placental bed). The

highest ZIKV RNA burden detected in a fetal membrane sample was from DENV-immune animal 042-104, which had a viral load of 1.03×10^5 vRNA copies/ml. We could not recover infectious virus from this specimen; we did not attempt virus isolation from other specimens, which had much lower viral loads ($<10^3$ copies/mg).

To determine whether the presence of vRNA in the MFI was associated with duration, peak, or area under the curve of viremia, we performed a Pearson correlation analysis. When prolonged viremia was defined as >21 days and non-prolonged viremia as <21 days (Fig. 6B) there was a significant positive correlation between prolonged viremia and presence of vRNA in the MFI for both the DENV-immune and DENV-naïve cohorts. When viremia is assessed as a continuous variable, the correlation is no longer significant for the DENV-immune cohort (Fig. 6C). There was a significant correlation between area under the curve and presence of vRNA in the MFI in both cohorts (Fig. 6D, 6E). There was a significant correlation between peak viremia and presence of vRNA in the MFI only in DENV-naïve animals (Fig. 6E).




Fig. 6. Maternal-Fetal Interface Viral Loads. All tissue samples were tested for the presence of viral RNA using ZIKV-specific QRT-PCR. A. All tissues >0.1 copy vRNA/mg tissue are shown above; only tissues with viral loads greater than the theoretical limit of quantification (3 copies vRNA/mg) were used for statistical analysis. A Mann-Whitney U test was used to assess statistically significant differences between the experimental groups ($**p<0.01$). B-E. Pearson correlation analysis was performed to assess correlation between the percent of tissues collected that were vRNA positive and the duration (B and C), peak (D), and area under the curve (E) of viremia.

More-severe histopathological changes inconsistently detected in DENV-immune macaques

Placental insufficiency due to virus-mediated damage could lead to poor fetal outcomes (53). In order to assess the impact of ZIKV infection on MFI health, we quantified inflammation and infarctions within the MFI. Qualitative pathological findings included transmural infarctions and neutrophilic deciduitis in the central cross-section of both placental discs examined, but these findings were observed in animals of all groups, including mock-infected animals, with no consistent patterns distinguishing groups. In order to quantitatively analyze placental pathology and identify any trends within and between cohorts, the center section of each placental disc was scored for 22 pathologic changes associated with fetal vascular malperfusion, maternal vascular malperfusion, and generalized placental disease (Supplementary Table 2). DENV-immune macaques had significantly higher scores in four pathologic changes in disc 1 (% transmural infarction, chronic villitis, avascular villi, and chronic retroplacental hemorrhage) and one pathologic change in disc 2 (chronic villitis) as compared to the mock-infected cohort (Supplemental Fig. 2) There were no significant differences between DENV-naïve animals and mock-infected animals.

Table 1. Placental cotyledon pathology

Group	Dam	% CHIV+ cotyledons	Infarcted cotyledons/total cotyledons (%)	Villous stromal calcifications (present/absent)	Vasculopathy (present/absent)	Placental weight (g)
Mock	044-105	0.0	5.88	Present	Absent	111.08
	044-106	0.0	12.5	Present	Absent	106.5
	044-107	0.0	0.0	Present	Present	144.48
	044-108	0.0	45.5	Present	Absent	122.92
DENV-naïve	044-101	0.0	25.0	Present	Absent	172.59
	044-102	0.0	33.3	Present	Absent	123.87
	044-103	0.0	0.0	Absent	Absent	134.49
	044-104	0.0	18.2	Absent	Absent	120.48
DENV-immune	042-101	0.0	21.43	Present	Absent	104.4
	042-102	7.69	7.69	Present	Absent	111.9
	042-103	0.0	0.00	Present	Absent	120.06
	042-104	0.0	26.67	Present	Absent	95.33
	042-105	0.0	25.00	Absent	Absent	119.97
	042-106	0.0	53.33	Present	Present	120.14
	042-107	0.0	28.57	Present	Absent	139.74
	042-108	0.0	33.33	Present	Absent	129.54

19

20 We also assessed a cross-section of each of the individual placental cotyledons, including
 21 the decidua basalis, for the presence of chronic histiocytic intervillitis (CHIV), infarctions,
 22 villous stromal calcifications, and vasculopathy (Table 1). Although infarctions and villous
 23 stromal calcifications were present in DENV-immune and DENV-naïve macaques, they were
 24 also present in mock-infected animals. There were no statistically significant differences
 25 between any of the groups for any of these pathologic features or placental weight. This
 26 suggests that the presence of some changes, such as multifocal areas of villous
 27 mineralization, may be a result of normal placental aging or a result of stress from
 28 experimental procedures, rather than from viral infection. These data underscore the
 29 necessity of mock-infected controls when assessing pathology.

30

31 **DISCUSSION**

32 This study provides the first comprehensive assessment of the impact of pre-existing DENV
 33 immunity on ZIKV pathogenesis during pregnancy in a translational NHP model. Macaques
 34 with previous DENV-2 infection supported robust replication of ZIKV and developed a
 35 robust neutralizing antibody response to ZIKV, suggesting that primary DENV-2 infection
 36 had no protective effect. We did not observe evidence of enhanced ZIKV replication in
 37 DENV-immune macaques as compared to DENV-naïve macaques. Neither intrauterine
 38 growth restriction nor adverse fetal outcomes were observed in either cohort. However, we
 39 did observe ZIKV RNA in the MFI in a greater number of DENV-immune macaques and a
 40 significantly greater burden of ZIKV RNA in the chorionic plate in DENV-immune macaques
 41 as compared to DENV-naïve macaques. Although we do not have any evidence of direct
 42 fetal infection, the increased presence of ZIKV in the chorionic plate in DENV-immune
 43 macaques suggests that the virus is capable of crossing the placental barrier and reaching
 44 the chorionic plate, which is on the fetal side of the placenta (54). This enhanced infection is
 45 consistent with prior studies that have shown increased replication of ZIKV in the placenta
 46 of mice and placental cells in the presence of DENV antibodies (34, 36, 37). The implications
 47 of increased infection of the placenta on fetal outcomes is unclear, since we observed no
 48 fetal demise nor any of the other clinical sequelae associated with CZS in offspring. This
 49 also suggests that the presence of ZIKV in the maternal-fetal interface is not a robust
 50 indicator of significant fetal harm in this model. Future studies will define the effects of
 51 DENV and ZIKV on infant outcomes, as developmental deficits are the most common
 52 adverse outcome of prenatal ZIKV exposure in humans (55).

53

54 We did observe an association between prolonged viremia, defined as lasting >21 days, and
 55 the presence of ZIKV vRNA in the maternal-fetal interface. Since 5 of 8 DENV-immune
 56 macaques had viremia greater than 21 days, while only 1 of 4 DENV-naïve animals did, it is
 57 tempting to speculate that prior DENV immunity may lead to longer viral replication and
 58 therefore greater ZIKV burden in the placenta. However, since we did not observe any
 59 statistically significant differences in the duration of viremia between the two groups,

perhaps due to a small sample size, we cannot make any definitive conclusions about the impact of prior DENV immunity on the duration of ZIKV viremia.

A significant strength of this study was our ability to assess ZIKV pathogenesis in a translational model in macaques with known infection histories. This allowed us to report detailed antibody dynamics throughout the course of infection, historical data that can be challenging to obtain in human cohort studies particularly during pregnancy. We confirmed the presence of low levels of cross-reactive antibodies present at the time of ZIKV challenge in our DENV-immune cohort. Twenty-eight days after ZIKV-challenge, we determined that PRNT50, but not PRNT90, titers were significantly higher in our DENV-immune cohort. We were particularly interested in this finding, since a higher ZIKV neutralization titer at the time of delivery has been associated with CZS in human cohort studies (39). However, at the time of delivery there were no significant differences in iELISA titers between cohorts.

As is common to non-human primate studies, ethical and financial constraints limited the number of variables that we were able to test in this study. A significant limitation of this study is the small group sizes used. Since the most severe effects of ZIKV only occur in a minority of cases, it is difficult to model the full spectrum of disease that women experience when infected with ZIKV during pregnancy. Small group sizes further limited our statistical power to detect significant differences between groups. In this study, we only tested a single DENV serotype; there is considerable evidence that the sequence of infecting DENV serotypes has an effect on subsequent enhancement or protection (for review see (20)). There is also considerable evidence that the pre-existing antibody titer at the time of secondary infection is associated with the risk of developing severe disease (2, 48). In this study, we had a relatively short window (1-3 months) between DENV and ZIKV infection, and a different interval between infection may have affected the titer of cross-reactive antibodies present at the time of ZIKV challenge. We tested a single ZIKV isolate, dose, and inoculation time point in gestation; changes to any of these parameters could have elicited more significant differences in maternal or fetal outcomes.

The relationship between flavivirus antibodies and disease outcomes is complex, depending on factors including antibody titer, specificity, and degree of sequence conservation among viruses. It is therefore difficult to comprehensively disentangle all these factors in a single experiment. More work is needed to understand the relationship between DENV immunity, viral infection of the placenta, and prolonged viremia. While there is a growing consensus that DENV may not enhance ZIKV in non-pregnant individuals, this study provides evidence that more research is needed to understand the risks associated with prior DENV immunity on ZIKV pathogenesis in pregnancy.

99 METHODS

00 Experimental design

01 This study was designed to assess the impact of pre-existing DENV immunity on ZIKV
 02 pathogenesis during pregnancy in a non-human primate model. Eight female non-pregnant
 03 Indian origin rhesus macaques (*Macaca mulatta*) were inoculated subcutaneously with 1×10^4
 04 PFU of DENV-2/US/BID-V594/2006. Approximately 1-3 months following DENV challenge,
 05 macaques were bred and became pregnant. All eight macaques were then inoculated
 06 subcutaneously with 1×10^4 PFU of ZIKV-PRVABC59 (ZIKV-PR) between 44-50 days of
 07 gestation (term is 165 ± 10 days). Macaques were monitored throughout the remainder of
 08 gestation. At approximately gestation day 160, infants were delivered via cesarean section
 09 and monitored for long-term development. A comprehensive set of maternal biopsies and
 10 maternal-fetal interface were collected for analysis. For the DENV-naïve group, four
 11 pregnant Indian origin rhesus macaques (*Macaca mulatta*) were inoculated subcutaneously
 12 with 1×10^4 PFU of ZIKV-PR between 44-50 days of gestation (term is 165 ± 10 days).
 13 Macaques were monitored throughout the remainder of gestation. At approximately
 14 gestation day 160, infants were delivered via cesarean section and monitored for long-term
 15 development. A comprehensive set of maternal biopsies and maternal-fetal interface were
 16 collected for analysis. A cohort of four pregnant PBS-inoculated animals served as a control
 17 group and underwent the same experimental regimen, including the sedation for all blood
 18 draws and ultrasounds, as the ZIKV-infected cohort. In order to minimize the number of
 19 animals used in studies of ZIKV pathogenesis, the DENV-naïve and mock-infected cohort
 20 have served as a control group for other studies (56).

22 Ethical approval

23 This study was approved by the University of Wisconsin College of Letters and Sciences
 24 and Vice Chancellor for Research and Graduate Education Centers Institutional Animal Care
 25 and Use Committee (Protocol numbers: G005401 and G006139).

27 Care and use of macaques

28 All macaque monkeys used in this study were cared for by the staff at the WNPRC in
 29 accordance with the regulations and guidelines outlined in the Animal Welfare Act and the
 30 Guide for the Care and Use of Laboratory Animals and the recommendations of the
 31 Weatherall report ([https://royalsociety.org/topics-policy/publications/2006/weatherall-](https://royalsociety.org/topics-policy/publications/2006/weatherall-report/)
 32 [report/](https://royalsociety.org/topics-policy/publications/2006/weatherall-report/)). All macaques used in the study were free of *Macacine herpesvirus 1*, simian
 33 retrovirus type D (SRV), simian T-lymphotropic virus type 1 (STLV), and simian
 34 immunodeficiency virus (SIV). For all procedures (including physical examinations, virus
 35 inoculations, ultrasound examinations, and blood collection), animals were anaesthetized
 36 with an intramuscular dose of ketamine (10 mg/kg). Blood samples were obtained using a
 37 vacutainer system or needle and syringe from the femoral or saphenous vein.

38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76

Cells and viruses

DENV-2/US/BID-V594/2006 was originally isolated from a human in Puerto Rico with one round of amplification on C6/36 cells. This DENV-2 isolate was obtained from BEI resources (NR-43280, Manassas, VA). Zika-virus/H.sapiens-tc/PUR/2015/PRVABC59_v3c2 (ZIKV-PR) was originally isolated from a human in Puerto Rico in 2015, with three rounds of amplification on Vero cells, was obtained from Brandy Russell (CDC, Fort Collins, CO, USA). African Green Monkey kidney cells (Vero; ATCC #CCL-81) were maintained in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS; Hyclone, Logan, UT), 2 mM L-glutamine, 1.5 g/L sodium bicarbonate, 100 U/ml penicillin, 100 µg/ml of streptomycin, and incubated at 37°C in 5% CO₂. *Aedes albopictus* mosquito cells (C6/36; ATCC #CRL-1660) were maintained in DMEM supplemented with 10% fetal bovine serum (FBS; Hyclone, Logan, UT), 2mM L-glutamine, 1.5 g/L sodium bicarbonate, 100 U/ml penicillin, 100 µg/ml of streptomycin, and incubated at 28°C in 5% CO₂. The cell lines were obtained from the American Type Culture Collection, were not further authenticated, and were not specifically tested for mycoplasma. Virus stocks were prepared by inoculation onto a confluent monolayer of C6/36 cells; a single, clarified stock was harvested for each virus, with a titer of 1.55 x 10⁵ PFU/ml for DENV-2 and 1.58 x 10⁷ PFU/ml for ZIKV-PR. Deep sequencing with limited PCR cycles confirmed that the DENV-2 virus stock was identical to the reported sequence in GenBank (EU482725) at the consensus level. Twelve nucleotide variants were detected at 5.3-16.1% frequency. Amplicon deep sequencing of ZIKV-PR virus stock using the methods described in Quick, et al. (57) revealed two consensus-level nucleotide substitutions in the stock as compared to the reported sequence in GenBank (KU501215), as well as seven other minor nucleotide variants detected at 5.3-30.6% frequency. Details on accessing sequence data can be found in the Data Accessibility section.

Plaque Assay

All titrations for virus quantification from virus stocks and screens for infectious ZIKV from macaque tissue were completed by plaque assay on Vero cell cultures as previously described (58). Briefly, duplicate wells were infected with 0.1 ml aliquots from serial 10-fold dilutions in growth media and virus was adsorbed for one hour. Following incubation, the inoculum was removed, and monolayers were overlaid with 3ml containing a 1:1 mixture of 1.2% oxoid agar and 2X DMEM (Gibco, Carlsbad, CA) with 10% (vol/vol) FBS and 2% (vol/vol) penicillin/streptomycin (100 U/ml penicillin, 100 µg/ml of streptomycin). Cells were incubated at 37°C in 5% CO₂ for four days for plaque development. Cell monolayers were then stained with 3 ml of overlay containing a 1:1 mixture of 1.2% oxoid agar and 2X DMEM with 2% (vol/vol) FBS, 2% (vol/vol) penicillin/streptomycin, and 0.33% neutral red (Gibco). Cells were incubated overnight at 37 °C and plaques were counted.

77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
00
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18

Inoculations

Inocula were prepared from a viral stock propagated on a confluent monolayer of C6/36 cells. The stocks were thawed, diluted in PBS to 10⁴ PFU/ml and loaded into a 1 mL syringe that was kept on ice until challenge. Animals were anesthetized as described above and 1 ml of inocula was delivered subcutaneously over the cranial dorsum. Animals were monitored closely following inoculation for any signs of an adverse reaction.

Ultrasound measurements

Ultrasound measurements were taken according to the procedures described previously (47). Briefly, dams were sedated with ketamine hydrochloride (10mg/kg) for weekly sonographic assessment to monitor the health of the fetus (heart rate) and to take fetal growth measurements, including the fetal femur length (FL), biparietal diameter (BPD), head circumference (HC), and abdominal circumference (AC). Weekly fetal measurements were plotted against mean measurement values and standard deviations for fetal macaques developed at the California National Primate Research Center (51, 52). Additional Doppler ultrasounds were taken as requested by veterinary staff.

Gestational age standardized growth parameters for fetal HC, BPD, AC, and FL were evaluated by calculating gestational age specific z-values from normative fetal growth parameters. Linear mixed effects modeling with animal-specific random effects was used to analyze the fetal growth trajectories with advancing gestational age. In order to account for differences in fetal growth parameters at the date of inoculation, changes in fetal growth parameters from date of inoculation (~day 50) were analyzed. That is, changes in fetal growth parameters from date of inoculation were regressed on gestational age (in weeks). An autoregressive correlation structure was used to account for correlations between repeated measurements of growth parameters over time. The growth trajectories were quantified by calculating the regression slope parameters which were reported along with the corresponding 95% confidence intervals (CI). Fetal growth was evaluated both within and between groups. All reported P-values are two-sided and P<0.05 was used to define statistical significance. Statistical analyses were conducted using SAS software (SAS Institute, Cary NC), version 9.4.

Viral RNA isolation from blood

Viral RNA was isolated from macaque blood samples as previously described (58, 59). Briefly, plasma was isolated from EDTA-anticoagulated whole blood on the day of collection either using Ficoll density centrifugation for 30 minutes at 1860 x g if the blood was being processed for PBMC, or it was centrifuged in the blood tube at 1400 x g for 15 minutes. The plasma layer was removed and transferred to a sterile 15 ml conical and spun at 670 x g for an additional 8 minutes to remove any remaining cells. Viral RNA was extracted from a 300 µL plasma aliquot using the Viral Total Nucleic Acid Kit (Promega, Madison, WI) on a Maxwell 16 MDx or Maxwell RSC 48 instrument (Promega, Madison, WI).

19

20 **Viral RNA isolation from tissues**

21 Tissue samples, cut to 0.5 cm thickness on at least one side, were stored in RNAlater at 4°C
 22 for 2-7 days. RNA was recovered from tissue samples using a modification of the method
 23 described by Hansen et al., 2013 (60). Briefly, up to 200 mg of tissue was disrupted in
 24 TRIzol (Lifetechnologies) with 2 x 5 mm stainless steel beads using the TissueLyser (Qiagen)
 25 for 3 minutes at 25 r/s twice. Following homogenization, samples in TRIzol were separated
 26 using Bromo-chloro-propane (Sigma). The aqueous phase was collected, and glycogen was
 27 added as a carrier. The samples were washed in isopropanol and ethanol precipitated. RNA
 28 was fully re-suspended in 5 mM tris pH 8.0.

29

30 **Quantitative reverse transcription PCR (QRT-PCR)**

31 vRNA isolated from both fluid and tissue samples was quantified by QRT-PCR as previously
 32 described (61). The RT-PCR was performed using either the SuperScript III Platinum One-
 33 Step Quantitative RT-PCR system (Invitrogen, Carlsbad, CA) or Taqman Fast Virus 1-step
 34 master mix (Applied Biosystems, Foster City, CA) on a LightCycler 96 or LightCycler 480
 35 instrument (Roche Diagnostics, Indianapolis, IN). Viral RNA concentration was determined
 36 by interpolation onto an internal standard curve composed of seven 10-fold serial dilutions
 37 of a synthetic ZIKV RNA fragment based on a ZIKV strain derived from French Polynesia
 38 that shares >99% similarity at the nucleotide level to the Puerto Rican strain used in the
 39 infections described in this manuscript.

40

41 **Statistical analysis of viral loads**

42 Plasma viral load curves were generated using GraphPad Prism software. The area under
 43 the curve of 0-10 d.p.i. was calculated using GraphPad software and a two-sample t-test
 44 was performed to assess differences in the peak, duration, and area under the curve of ZIKV
 45 viremia between DENV-immune and DENV-naïve macaques. Duration was calculated both
 46 as a raw number of days and as a binary, with >21 days of viremia considered “prolonged”
 47 and <21 days considered “non-prolonged.” To compare differences in the viral burden in
 48 the maternal-fetal interface, a non-parametric Mann-Whitney U test was used to assess
 49 differences in each of the maternal-fetal interface tissues. GraphPad Prism 8 software was
 50 used for these analyses.

51

52 **Plaque reduction neutralization test (PRNT)**

53 Macaque serum was isolated from whole blood on the same day it was collected using a
 54 serum separator tube (SST) or clot activator (CA) tube. The SST or CA tube was centrifuged
 55 for at least 20 minutes at 1400 x g, the serum layer was removed and placed in a 15 ml
 56 conical and centrifuged for 8 minutes at 670 x g to remove any additional cells. Serum was
 57 screened for ZIKV neutralizing antibody utilizing a plaque reduction neutralization test
 58 (PRNT) on Vero cells as described in (62) against DENV-2 and ZIKV-PR. Neutralization
 59 curves were generated using GraphPad Prism 8 software. The resulting data were analyzed

by non-linear regression to estimate the dilution of serum required to inhibit 50% and 90% of infection.

Inhibition ELISA (iELISA assay) The DENV iELISA was performed on serum samples as previously described (2, 63, 64). Briefly, ELISA plates were coated with anti-DENV polyclonal IgG to capture a mixture of DENV 1-4 antigen (DENV prototype strains, GenBank Accession #s: KM204119, KM204118, KU050695, KR011349) diluted in Phosphate Buffer Saline + 0.05% Tween 20 at pH 7.4 (PBS-T)(65). After blocking and additional washes, macaque serum was added in 10-fold serial dilutions (1:10, 1:100, 1:1000, 1:10,000) and incubated for two hours at 37°C. Thereafter, a set concentration of horseradish peroxidase (HRP)-conjugated polyclonal anti-DENV IgG to each well and incubated for 30 minutes at 37°C. Following washes, peroxidase substrate TMB was added to wells and incubated for 30 minutes at room temperature, then stopped with sulfuric acid. Plates were read on an ELISA reader, and iELISA titers were estimated relative to negative controls (conjugated antibody only) using the Reed-Muench method (66). The ZIKV iELISA is similar in design to the DENV iELISA and was performed as described previously (67). ZIKV-specific monoclonal antibody ZKA64 (68) is used to capture ZIKV antigen prepared as described by (65), macaque serum was added in serial dilutions and competed with HRP-conjugated mAb ZKA64, and iELISA titers were also estimated using the Reed-Muench method.

Cesarean section and tissue collection

Between 159-161 days gestation, infants were delivered via cesarean section and tissues were collected. The fetus, placenta, fetal membranes, umbilical cord, and amniotic fluid were collected at surgical uterotomy and maternal tissues were biopsied during laparotomy. These were survival surgeries for the dams and offspring. Amniotic fluid was removed from the amniotic sac, then infant was removed from the amniotic sac, the umbilical cord clamped, and neonatal resuscitation performed as needed. The placenta and fetal membranes were then collected. Infants were placed with their mothers following the dam's recovery from surgery.

Tissues were dissected as previously described (47) using sterile instruments that were changed between each organ and tissue type to minimize possible cross contamination. Each organ/tissue was evaluated grossly, dissected with sterile instruments in a sterile culture dish, and sampled for histology, viral burden assay, and/or banked for future assays. A comprehensive listing of all specific tissues collected and analyzed is presented in Fig. 6A (maternal-fetal interface tissues) and Supplementary Table 2 (maternal biopsies and fetal fluids). Biopsies of the placental bed (uterine placental attachment site containing deep decidua basalis and myometrium), maternal liver, spleen, and a mesenteric lymph node were collected aseptically during surgery into sterile petri dishes, weighed, and further processed for viral burden and when sufficient sample size was obtained, histology.

In order to more accurately capture the distribution of ZIKV in the placenta, each placental disc was separated, fetal membranes sharply dissected from the margin, weighed, measured, and placed in a sterile dish on ice. A 1-cm-wide cross section was taken from the center of each disc, including the umbilical cord insertion on the primary disc, and placed in 4% paraformaldehyde. Individual cotyledons, or perfusion domains, were dissected using a scalpel and placed into individual petri dishes. From each cotyledon, a thin center cut was taken using a razor blade and placed into a cassette in 4% paraformaldehyde. Once the center cut was collected, the decidua and the chorionic plate were removed from the remaining placenta. From each cotyledon, pieces of decidua, chorionic plate, and chorionic villi were collected into two different tubes – one with RNAlater for vRNA isolation and one with 20% FBS/PBS for other virological assays.

Histology

Following collection, tissues were handled as described previously (58). All tissues were fixed in 4% paraformaldehyde for 24 hours and transferred into 70% ethanol until processed and embedded in paraffin. Paraffin sections (5 µm) were stained with hematoxylin and eosin (H&E). Pathologists were blinded to vRNA findings when tissue sections were evaluated microscopically. Photomicrographs were obtained using a bright light microscope Olympus BX43 and Olympus BX46 (Olympus Inc., Center Valley, PA) with attached Olympus DP72 digital camera (Olympus Inc.) and Spot Flex 152 64 Mp camera (Spot Imaging) and captured using commercially available image-analysis software (cellSens DimensionR, Olympus Inc. and spot software 5.2).

Placental Histology Scoring

Pathological evaluation of the cross-sections of each of the individual placental cotyledons were performed by Dr. Terry Morgan who was blinded to experimental condition. Each of the cross sections were evaluated for the presence of chronic histiocytic intervillitis (CHIV), infarctions, villous stromal calcifications, and vasculopathy. A three-way ANOVA was performed to assess statistical significance among groups for each parameter, including placental weight.

Two of three boarded veterinary pathologists, blinded to vRNA findings, independently reviewed the central cross section of each placental disc and quantitatively scored the placentas on 22 independent criteria. Six of the criteria are general criteria assessing placental function, two assess villitis, three criteria assess the presence of fetal vascular malperfusion, and 11 criteria assess the presence of maternal vascular malperfusion. The scoring system was developed by Dr. Michael Fritsch, Dr. Heather Simmons, and Dr. Andres Mejia. A summary table of the criteria scored, and the scale used for each criterion can be found in Supplementary Table 3. Once initial scores were assigned, all pathologists met to discuss and resolve any significant discrepancies in scoring. Scores were assigned to each placental disc unless the criteria scored corresponded to the function of the entire placenta.

43

44 For criteria measured on a quantitative scale, median scores and interquartile range were
 45 calculated for each experimental group. For criteria measured on a binary “present/not
 46 present” scale, the cumulative incidence in each experimental group was calculated as a
 47 frequency and a percentage. For quantitative criteria, a non-parametric Wilcoxon rank test
 48 was used to calculate statistical significance between each of the groups and between the
 49 mock-infected group and the two ZIKV-infected groups. For binary features, Fisher’s exact
 50 test was used to calculate statistical significance between each of the groups and between
 51 the mock-infected group and the two ZIKV-infected groups. To determine whether chronic
 52 villitis correlated with the criteria assessing fetal malperfusion and whether chronic
 53 decidualitis correlated with the criteria assessing maternal malperfusion, scores were adjusted
 54 to be on the same scale (i.e., converting measures on a 0-1 scale to a 0-2 scale) so that
 55 each parameter carried equal weight in the combined score. A nonparametric Spearman's
 56 correlation was used to determine the correlation.

57

58 REFERENCES

- 59 1. Ngono, A. E., and S. Shresta. 2018. Immune Response to Dengue and Zika. *Annu Rev*
 60 *Immunol* 36: 279-308.
- 61 2. Katzelnick, L. C., L. Gresh, M. E. Halloran, J. C. Mercado, G. Kuan, A. Gordon, A.
 62 Balmaseda, and E. Harris. 2017. Antibody-dependent enhancement of severe dengue
 63 disease in humans. *Science* 358: 929-932.
- 64 3. Halstead, S. B., and E. J. O’Rourke. 1977. Dengue viruses and mononuclear
 65 phagocytes. I. Infection enhancement by non-neutralizing antibody. *J Exp Med* 146: 201-
 66 217.
- 67 4. Whitehead, S. S., J. E. Blaney, A. P. Durbin, and B. R. Murphy. 2007. Prospects for a
 68 dengue virus vaccine. *Nat Rev Microbiol* 5: 518-528.
- 69 5. Halstead, S. B. 2014. Dengue Antibody-Dependent Enhancement: Knowns and
 70 Unknowns. In *Antibodies for Infectious Diseases*, ed. American Society of Microbiology,
 71 p. 249-271.
- 72 6. Kam, Y. W., C. Y. Lee, T. H. Teo, S. W. Howland, S. N. Amrun, F. M. Lum, P. See, N. Q.
 73 Kng, R. G. Huber, M. H. Xu, H. L. Tan, A. Choo, S. Maurer-Stroh, F. Ginhoux, K. Fink, C.
 74 I. Wang, L. F. Ng, and L. Rénia. 2017. Cross-reactive dengue human monoclonal
 75 antibody prevents severe pathologies and death from Zika virus infections. *JCI Insight* 2:
 76 7. Bardina, S. V., P. Bunduc, S. Tripathi, J. Duehr, J. J. Frere, J. A. Brown, R. Nachbagauer,
 77 G. A. Foster, D. Krysztof, D. Tortorella, S. L. Stramer, A. García-Sastre, F. Krammer, and
 78 J. K. Lim. 2017. Enhancement of Zika virus pathogenesis by preexisting ant flavivirus
 79 immunity. *Science* 356: 175-180.
- 80 8. Castanha, P. M. S., E. J. M. Nascimento, B. Cynthia, M. T. Cordeiro, O. V. de Carvalho,
 81 L. R. de Mendonça, E. A. N. Azevedo, R. F. O. França, D. Rafael, and E. T. A. Marques.
 82 2017. Dengue virus (DENV)-specific antibodies enhance Brazilian Zika virus (ZIKV)
 83 infection. *Journal of Infectious Diseases* jiw638.

- 84 9. Londono-Renteria, B., A. Troupin, J. C. Cardenas, A. Hall, O. G. Perez, L. Cardenas, A.
85 Hartstone-Rose, S. B. Halstead, and T. M. Colpitts. 2017. A relevant in vitro human
86 model for the study of Zika virus antibody-dependent enhancement. *Journal of General*
87 *Virology* 98: 1702-1712.
- 88 10. Priyamvada, L., K. M. Quicke, W. H. Hudson, N. Onlamoon, J. Sewatanon, S.
89 Edupuganti, K. Pattanapanyasat, K. Chokephaibulkit, M. J. Mulligan, P. C. Wilson, R.
90 Ahmed, M. S. Suthar, and J. Wrammert. 2016. Human antibody responses after dengue
91 virus infection are highly cross-reactive to Zika virus. *Proc Natl Acad Sci U S A* 113:
92 7852-7857.
- 93 11. Li, M., L. Zhao, C. Zhang, X. Wang, W. Hong, J. Sun, R. Liu, L. Yu, J. Wang, F. Zhang,
94 and X. Jin. 2018. Dengue immune sera enhance Zika virus infection in human peripheral
95 blood monocytes through Fc gamma receptors. *PLoS One* 13: e0200478.
- 96 12. Dejnirattisai, W., P. Supasa, W. Wongwiwat, A. Rouvinski, G. Barba-Spaeth, T.
97 Duangchinda, A. Sakuntabhai, V.-M. Cao-Lormeau, P. Malasit, F. A. Rey, J.
98 Mongkolsapaya, and G. R. Screaton. 2016. Dengue virus sero-cross-reactivity drives
99 antibody-dependent enhancement of infection with zika virus. *Nature Immunology* 17:
00 1102-1108.
- 01 13. Swanstrom, J. A., J. A. Plante, K. S. Plante, E. F. Young, E. McGowan, E. N. Gallichotte,
02 D. G. Widman, M. T. Heise, A. M. de Silva, and R. S. Baric. 2016. Dengue Virus Envelope
03 Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective
04 against Zika Virus. *mBio* 7:
- 05 14. Collins, M. H., E. McGowan, R. Jadi, E. Young, C. A. Lopez, R. S. Baric, H. M. Lazear,
06 and A. M. de Silva. 2017. Lack of Durable Cross-Neutralizing Antibodies Against Zika
07 Virus from Dengue Virus Infection. *Emerg Infect Dis* 23: 773-781.
- 08 15. Montoya, M., M. Collins, W. Dejnirattisai, L. C. Katzelnick, H. Puerta-Guardo, R. Jadi, S.
09 Schildhauer, P. Supasa, S. Vasanawathana, P. Malasit, J. Mongkolsapaya, A. D. de
10 Silva, H. Tissera, A. Balmaseda, G. Screaton, A. M. de Silva, and E. Harris. 2018.
11 Longitudinal Analysis of Antibody Cross-neutralization Following Zika Virus and Dengue
12 Virus Infection in Asia and the Americas. *J Infect Dis* 218: 536-545.
- 13 16. Zhang, S., T. Loy, T. S. Ng, X. N. Lim, S. V. Chew, T. Y. Tan, M. Xu, V. A. Kostyuchenko,
14 F. Tukijan, J. Shi, K. Fink, and S. M. Lok. 2020. A Human Antibody Neutralizes Different
15 Flaviviruses by Using Different Mechanisms. *Cell Rep* 31: 107584.
- 16 17. Regla-Nava, J. A., A. Elong Ngono, K. M. Viramontes, A. T. Huynh, Y. T. Wang, A. T.
17 Nguyen, R. Salgado, A. Mamidi, K. Kim, M. S. Diamond, and S. Shresta. 2018. Cross-
18 reactive Dengue virus-specific CD8⁺ T cells protect against Zika virus during pregnancy.
19 *Nat Commun* 9: 3042.
- 20 18. Wen, J., A. Elong Ngono, J. A. Regla-Nava, K. Kim, M. J. Gorman, M. S. Diamond, and
21 S. Shresta. 2017. Dengue virus-reactive CD8⁺ T cells mediate cross-protection against
22 subsequent Zika virus challenge. *Nat Commun* 8: 1459.
- 23 19. Wen, J., Y. T. Wang, K. M. Valentine, R. P. Dos Santos Alves, Z. Xu, J. A. Regla-Nava, A.
24 E. Ngono, M. P. Young, L. C. S. Ferreira, and S. Shresta. 2020. CD4⁺ T Cells Cross-

- Reactive with Dengue and Zika Viruses Protect against Zika Virus Infection. *Cell Rep* 31: 107566.
20. Katzelnick, L. C., S. Bos, and E. Harris. 2020. Protective and enhancing interactions among dengue viruses 1-4 and Zika virus. *Curr Opin Virol* 43: 59-70.
21. Rodriguez-Barraquer, I., F. Costa, E. J. M. Nascimento, N. Nery, P. M. S. Castanha, G. A. Sacramento, J. Cruz, M. Carvalho, D. De Olivera, J. E. Hagan, H. Adhikarla, E. A. Wunder, D. F. Coêlho, S. R. Azar, S. L. Rossi, N. Vasilakis, S. C. Weaver, G. S. Ribeiro, A. Balmaseda, E. Harris, M. L. Nogueira, M. G. Reis, E. T. A. Marques, D. A. T. Cummings, and A. I. Ko. 2019. Impact of preexisting dengue immunity on Zika virus emergence in a dengue endemic region. *Science* 363: 607-610.
22. Santiago, G. A., T. M. Sharp, E. Rosenberg, I. I. Sosa Cardona, L. Alvarado, G. Paz-Bailey, and J. L. Muñoz-Jordán. 2019. Prior Dengue Virus Infection Is Associated With Increased Viral Load in Patients Infected With Dengue but Not Zika Virus. *Open Forum Infect Dis* 6:
23. Gordon, A., L. Gresh, S. Ojeda, L. C. Katzelnick, N. Sanchez, J. C. Mercado, G. Chowell, B. Lopez, D. Elizondo, J. Coloma, R. Burger-Calderon, G. Kuan, A. Balmaseda, and E. Harris. 2019. Prior dengue virus infection and risk of Zika: A pediatric cohort in Nicaragua. *PLoS Med* 16: e1002726.
24. Michlmayr, D., E. Y. Kim, A. H. Rahman, R. Raghunathan, S. Kim-Schulze, Y. Che, S. Kalayci, Z. H. Gümüş, G. Kuan, A. Balmaseda, A. Kasarskis, S. M. Wolinsky, M. Suárez-Fariñas, and E. Harris. 2020. Comprehensive Immunoprofiling of Pediatric Zika Reveals Key Role for Monocytes in the Acute Phase and No Effect of Prior Dengue Virus Infection. *Cell Rep* 31: 107569.
25. Tonnerre, P., J. G. Melgaço, A. Torres-Cornejo, M. A. Pinto, C. Yue, J. Blümel, P. S. F. de Sousa, V. D. M. de Mello, J. Moran, A. M. B. de Filippis, D. Wolski, A. Grifoni, A. Sette, D. H. Barouch, R. C. Hoogeveen, S. A. Baylis, G. M. Lauer, and L. L. Lewis-Ximenez. 2020. Evolution of the innate and adaptive immune response in women with acute Zika virus infection. *Nat Microbiol* 5: 76-83.
26. McCracken, M. K., G. D. Gromowski, H. L. Friberg, X. Lin, P. Abbink, R. De La Barrera, K. H. Eckles, L. S. Garver, M. Boyd, D. Jetton, D. H. Barouch, M. C. Wise, B. S. Lewis, J. R. Currier, K. Modjarrad, M. Milazzo, M. Liu, A. B. Mullins, J. R. Putnak, N. L. Michael, R. G. Jarman, and S. J. Thomas. 2017. Impact of prior flavivirus immunity on Zika virus infection in rhesus macaques. *PLoS Pathog* 13: e1006487.
27. Pantoja, P., E. X. Pérez-Guzmán, I. V. Rodríguez, L. J. White, O. González, C. Serrano, L. Giavedoni, V. Hodara, L. Cruz, T. Arana, M. I. Martínez, M. A. Hassert, J. D. Brien, A. K. Pinto, A. de Silva, and C. A. Sariol. 2017. Zika virus pathogenesis in rhesus macaques is unaffected by pre-existing immunity to dengue virus. *Nat Commun* 8: 15674.
28. Breitbach, M. E., C. M. Newman, D. M. Dudley, L. M. Stewart, M. T. Aliota, M. R. Koenig, P. M. Shepherd, K. Yamamoto, C. M. Crooks, G. Young, M. R. Semler, A. M. Weiler, G. L. Barry, H. Heimsath, E. L. Mohr, J. Eichkoff, W. Newton, E. Peterson, N. Schultz-Darken, S. R. Permar, H. Dean, S. Capuano, J. E. Osorio, T. C. Friedrich, and D. H.

- O'Connor. 2019. Primary infection with dengue or Zika virus does not affect the severity of heterologous secondary infection in macaques. *PLoS Pathog* 15: e1007766.
29. Abbink, P., R. A. Larocca, W. Dejnirattisai, R. Peterson, J. P. Nkolola, E. N. Borducchi, P. Supasa, J. Mongkolsapaya, G. R. Screaton, and D. H. Barouch. 2018. Therapeutic and protective efficacy of a dengue antibody against Zika infection in rhesus monkeys. *Nat Med*
30. Cao-Lormeau, V. M., C. Roche, M. Aubry, A. Teissier, S. Lastere, E. Daudens, H. P. Mallet, D. Musso, and J. Aaskov. 2011. Recent emergence of dengue virus serotype 4 in French Polynesia results from multiple introductions from other South Pacific Islands. *PLoS One* 6: e29555.
31. Savage, H. M., C. L. Fritz, D. Rutstein, A. Yolwa, V. Vorndam, and D. J. Gubler. 1998. Epidemic of dengue-4 virus in Yap State, Federated States of Micronesia, and implication of Aedes hensilli as an epidemic vector. *Am J Trop Med Hyg* 58: 519-524.
32. Durand, M. A., M. Bel, I. Ruwey, M. Marfel, L. Yug, and V. Ngaden. 2005. An outbreak of dengue fever in Yap State. *Pac Health Dialog* 12: 99-102.
33. Dupont-Rouzeyrol, M., O. O'Connor, E. Calvez, M. Daurès, M. John, J. P. Grangeon, and A. C. Gourinat. 2015. Co-infection with Zika and dengue viruses in 2 patients, New Caledonia, 2014. *Emerg Infect Dis* 21: 381-382.
34. Zimmerman, M. G., K. M. Quicke, J. T. O'Neal, N. Arora, D. Machiah, L. Priyamvada, R. C. Kauffman, E. Register, O. Adekunle, D. Swieboda, E. L. Johnson, S. Cordes, L. Haddad, R. Chakraborty, C. B. Coyne, J. Wrammert, and M. S. Suthar. 2018. Cross-Reactive Dengue Virus Antibodies Augment Zika Virus Infection of Human Placental Macrophages. *Cell Host Microbe* 24: 731-742.e6.
35. Hermanns, K., C. Göhner, A. Kopp, A. Schmidt, W. M. Merz, U. R. Markert, S. Junglen, and C. Drosten. 2018. Zika virus infection in human placental tissue explants is enhanced in the presence of dengue virus antibodies in-vitro. *Emerg Microbes Infect* 7: 198.
36. Brown, J. A., G. Singh, J. A. Acklin, S. Lee, J. E. Duehr, A. N. Chokola, J. J. Frere, K. W. Hoffman, G. A. Foster, D. Kryzstof, R. Cadagan, A. R. Jacobs, S. L. Stramer, F. Krammer, A. García-Sastre, and J. K. Lim. 2019. Dengue Virus Immunity Increases Zika Virus-Induced Damage during Pregnancy. *Immunity* 50: 1-12.
37. Rathore, A. P. S., W. A. A. Saron, T. Lim, N. Jahan, and A. L. St John. 2019. Maternal immunity and antibodies to dengue virus promote infection and Zika virus-induced microcephaly in fetuses. *Sci Adv* 5: eaav3208.
38. Halai, U. A., K. Nielsen-Saines, M. L. Moreira, P. C. de Sequeira, J. P. P. Junior, A. de Araujo Zin, J. Cherry, C. R. Gabaglia, S. L. Gaw, K. Adachi, I. Tsui, J. H. Pilotto, R. R. Nogueira, A. M. B. de Filippis, and P. Brasil. 2017. Maternal Zika Virus Disease Severity, Virus Load, Prior Dengue Antibodies, and Their Relationship to Birth Outcomes. *Clin Infect Dis* 65: 877-883.
39. Moreira-Soto, A., M. Sarno, C. Pedroso, E. M. Netto, A. Rockstroh, E. Luz, M. Feldmann, C. Fischer, F. A. Bastos, B. M. Kümmerer, X. de Lamballerie, C. Drosten, S. Ulbert, C. Brites, and J. F. Drexler. 2017. Evidence for Congenital Zika Virus Infection From

- Neutralizing Antibody Titers in Maternal Sera, Northeastern Brazil. *J Infect Dis* 216: 1501-1504.
40. Castanha, P. M. S., W. V. Souza, C. Braga, T. V. B. Araújo, R. A. A. Ximenes, M. F. P. M. Albuquerque, U. R. Montarroyos, D. B. Miranda-Filho, M. T. Cordeiro, R. Dhalia, E. T. A. Marques, L. C. Rodrigues, C. M. T. Martelli, and E. R. G. Microcephaly. 2019. Perinatal analyses of Zika- and dengue virus-specific neutralizing antibodies: A microcephaly case-control study in an area of high dengue endemicity in Brazil. *PLoS Negl Trop Dis* 13: e0007246.
41. Carvalho, M. S., L. P. Freitas, O. G. Cruz, P. Brasil, and L. S. Bastos. 2020. Association of past dengue fever epidemics with the risk of Zika microcephaly at the population level in Brazil. *Sci Rep* 10: 1752.
42. Diamond, M. S., J. E. Ledgerwood, and T. C. Pierson. 2019. Zika Virus Vaccine Development: Progress in the Face of New Challenges. *Annu Rev Med* 70: 121-135.
43. Barba-Spaeth, G., W. Dejnirattisai, A. Rouvinski, M. C. Vaney, I. Medits, A. Sharma, E. Simon-Lorière, A. Sakuntabhai, V. M. Cao-Lormeau, A. Haouz, P. England, K. Stiasny, J. Mongkolsapaya, F. X. Heinz, G. R. Screaton, and F. A. Rey. 2016. Structural basis of potent Zika-dengue virus antibody cross-neutralization. *Nature* 536: 48-53.
44. Rey, F. A., K. Stiasny, M. C. Vaney, M. Dellarole, and F. X. Heinz. 2018. The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design. *EMBO Rep* 19: 206-224.
45. Halstead, S. B. 2017. Dengvaxia sensitizes seronegatives to vaccine enhanced disease regardless of age. *Vaccine* 35: 6355-6358.
46. Newman, C., T. C. Friedrich, and D. H. O'Connor. 2017. Macaque monkeys in Zika virus research: 1947-present. *Curr Opin Virol* 25: 34-40.
47. Nguyen, S. M., K. M. Antony, D. M. Dudley, S. Kohn, H. A. Simmons, B. Wolfe, M. S. Salamat, L. B. C. Teixeira, G. J. Wiepz, T. H. Thoong, M. T. Aliota, A. M. Weiler, G. L. Barry, K. L. Weisgrau, L. J. Vosler, M. S. Mohns, M. E. Breitbach, L. M. Stewart, M. N. Rasheed, C. M. Newman, M. E. Graham, O. E. Wieben, P. A. Turski, K. M. Johnson, J. Post, J. M. Hayes, N. Schultz-Darken, M. L. Schotzko, J. A. Eudailey, S. R. Permar, E. G. Rakasz, E. L. Mohr, S. Capuano, A. F. Tarantal, J. E. Osorio, S. L. O'Connor, T. C. Friedrich, D. H. O'Connor, and T. G. Golos. 2017. Highly efficient maternal-fetal Zika virus transmission in pregnant rhesus macaques. *PLoS Pathog* 13: e1006378.
48. Salje, H., D. A. T. Cummings, I. Rodriguez-Barraquer, L. C. Katzelnick, J. Lessler, C. Klungthong, B. Thaisomboonsuk, A. Nisalak, A. Weg, D. Ellison, L. Macareo, I. K. Yoon, R. Jarman, S. Thomas, A. L. Rothman, T. Endy, and S. Cauchemez. 2018. Reconstruction of antibody dynamics and infection histories to evaluate dengue risk. *Nature* 557: 719-723.
49. Katzelnick, L. C., C. Narvaez, S. Arguello, B. Lopez Mercado, D. Collado, O. Ampie, D. Elizondo, T. Miranda, F. Bustos Carillo, J. C. Mercado, K. Latta, A. Schiller, B. Segovia-Chumbez, S. Ojeda, N. Sanchez, M. Plazaola, J. Coloma, M. E. Halloran, L. Premkumar, A. Gordon, F. Narvaez, A. M. de Silva, G. Kuan, A. Balmaseda, and E. Harris. 2020. Zika virus infection enhances future risk of severe dengue disease. *Science* 369: 1123-1128.

- 50 50. Abbink, P., R. A. Larocca, K. Visitsunthorn, M. Boyd, A. Rafael, G. D. Gromowski, M.
51 Kirilova, R. Peterson, Z. Li, and O. Nanayakkara. 2017. Durability and correlates of
52 vaccine protection against Zika virus in rhesus monkeys. *Science translational medicine*
53 9:
- 54 51. Tarantal, A. F., and A. G. Hendrickx. 1988. Prenatal growth in the cynomolgus and
55 rhesus macaque (*Macaca fascicularis* and *Macaca mulatta*): A comparison by
56 ultrasonography. *Am J Primatol* 15: 309-323.
- 57 52. Tarantal, A. F. 2005. Ultrasound Imaging in Rhesus (*Macaca Mulatta*) and Long-Tailed
58 (*Macaca fascicularis*) Macaques. Reproductive and Research Applications. The
59 Laboratory Primate: 317-352.
- 60 53. Gynecologists, A. C. O. O. A. 2019. ACOG Practice Bulletin No. 204: fetal growth
61 restriction. *Obstetrics and gynecology* 133: e97-e109.
- 62 54. Arora, N., Y. Sadovsky, T. S. Dermody, and C. B. Coyne. 2017. Microbial Vertical
63 Transmission during Human Pregnancy. *Cell Host Microbe* 21: 561-567.
- 64 55. Nielsen-Saines, K., P. Brasil, T. Kerin, Z. Vasconcelos, C. R. Gabaglia, L. Damasceno, M.
65 Pone, L. M. Abreu de Carvalho, S. M. Pone, A. A. Zin, I. Tsui, T. R. S. Salles, D. C. da
66 Cunha, R. P. Costa, J. Malacarne, A. B. Reis, R. H. Hasue, C. Y. P. Aizawa, F. F.
67 Genovesi, C. Einspieler, P. B. Marschik, J. P. Pereira, S. L. Gaw, K. Adachi, J. D. Cherry,
68 Z. Xu, G. Cheng, and M. E. Moreira. 2019. Delayed childhood neurodevelopment and
69 neurosensory alterations in the second year of life in a prospective cohort of ZIKV-
70 exposed children. *Nat Med* 25: 1213-1217.
- 71 56. Crooks, C. M., A. M. Weiler, S. L. Rybarczyk, M. I. Bliss, A. S. Jaeger, M. E. Murphy, H.
72 A. Simmons, A. Mejia, M. K. Fritsch, J. M. Hayes, J. C. Eickhoff, A. M. Mitzey, E. Razo,
73 K. Braun, E. A. Brown, K. Yamamoto, P. M. Shepard, A. Possell, K. Weaver, K. M.
74 Antony, T. K. Morgan, D. Dudley, E. Peterson, N. Schultz-Darken, D. H. O'Connor, E. L.
75 Mohr, T. G. Golos, M. Aliota, and T. C. Friedrich. 2020. African-lineage Zika virus
76 replication dynamics and maternal-fetal interface infection in pregnant rhesus macaques.
77 *biorxiv*
- 78 57. Quick, J., N. D. Grubaugh, S. T. Pullan, I. M. Claro, A. D. Smith, K. Gangavarapu, G.
79 Oliveira, R. Robles-Sikisaka, T. F. Rogers, N. A. Beutler, D. R. Burton, L. L. Lewis-
80 Ximenez, J. G. de Jesus, M. Giovanetti, S. C. Hill, A. Black, T. Bedford, M. W. Carroll, M.
81 Nunes, L. C. Alcantara, E. C. Sabino, S. A. Baylis, N. R. Faria, M. Loose, J. T. Simpson,
82 O. G. Pybus, K. G. Andersen, and N. J. Loman. 2017. Multiplex PCR method for MinION
83 and Illumina sequencing of Zika and other virus genomes directly from clinical samples.
84 *Nat Protoc* 12: 1261-1276.
- 85 58. Aliota, M. T., D. M. Dudley, C. M. Newman, J. Weger-Lucarelli, L. M. Stewart, M. R.
86 Koenig, M. E. Breitbach, A. M. Weiler, M. R. Semler, G. L. Barry, K. R. Zarbock, A. K. Haj,
87 R. V. Moriarty, M. S. Mohns, E. L. Mohr, V. Venturi, N. Schultz-Darken, E. Peterson, W.
88 Newton, M. L. Schotzko, H. A. Simmons, A. Mejia, J. M. Hayes, S. Capuano, M. P.
89 Davenport, T. C. Friedrich, G. D. Ebel, S. L. O'Connor, and D. H. O'Connor. 2018.
90 Molecularly barcoded Zika virus libraries to probe in vivo evolutionary dynamics. *PLoS*
91 *Pathog* 14: e1006964.

59. Dudley, D. M., M. T. Aliota, E. L. Mohr, A. M. Weiler, G. Lehrer-Brey, K. L. Weisgrau, M. S. Mohns, M. E. Breitbach, M. N. Rasheed, C. M. Newman, D. D. Gellerup, L. H. Moncla, J. Post, N. Schultz-Darken, M. L. Schotzko, J. M. Hayes, J. A. Eudailey, M. A. Moody, S. R. Permar, S. L. O'Connor, E. G. Rakasz, H. A. Simmons, S. Capuano, T. G. Golos, J. E. Osorio, T. C. Friedrich, and D. H. O'Connor. 2016. A rhesus macaque model of Asian-lineage Zika virus infection. *Nat Commun* 7: 12204.
60. Hansen, S. G., M. Piatak, A. B. Ventura, C. M. Hughes, R. M. Gilbride, J. C. Ford, K. Oswald, R. Shoemaker, Y. Li, M. S. Lewis, A. N. Gilliam, G. Xu, N. Whizin, B. J. Burwitz, S. L. Planer, J. M. Turner, A. W. Legasse, M. K. Axthelm, J. A. Nelson, K. Früh, J. B. Sacha, J. D. Estes, B. F. Keele, P. T. Edlefsen, J. D. Lifson, and L. J. Picker. 2013. Immune clearance of highly pathogenic SIV infection. *Nature* 502: 100-104.
61. Jaeger, A. S., R. A. Murrieta, L. R. Goren, C. M. Crooks, R. V. Moriarty, A. M. Weiler, S. Rybarczyk, M. R. Semler, C. Huffman, A. Mejia, H. A. Simmons, M. Fritsch, J. E. Osorio, J. C. Eickhoff, S. L. O'Connor, G. D. Ebel, T. C. Friedrich, and M. T. Aliota. 2019. Zika viruses of African and Asian lineages cause fetal harm in a mouse model of vertical transmission. *PLoS Negl Trop Dis* 13: e0007343.
62. Lindsey, H. S., C. H. Calisher, and J. H. Mathews. 1976. Serum dilution neutralization test for California group virus identification and serology. *J Clin Microbiol* 4: 503-510.
63. Balmaseda, A., S. N. Hammond, Y. Tellez, L. Imhoff, Y. Rodriguez, S. I. Saborío, J. C. Mercado, L. Perez, E. Videa, E. Almanza, G. Kuan, M. Reyes, L. Saenz, J. J. Amador, and E. Harris. 2006. High seroprevalence of antibodies against dengue virus in a prospective study of schoolchildren in Managua, Nicaragua. *Trop Med Int Health* 11: 935-942.
64. Fernández, R. J., and S. Vázquez. 1990. Serological diagnosis of dengue by an ELISA inhibition method (EIM). *Mem Inst Oswaldo Cruz* 85: 347-351.
65. CLARKE, D. H., and J. CASALS. 1958. Techniques for hemagglutination and hemagglutination-inhibition with arthropod-borne viruses. *Am J Trop Med Hyg* 7: 561-573.
66. Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty per cent endpoints. *American journal of epidemiology* 27: 493-497.
67. Balmaseda, A., J. V. Zambrana, D. Collado, N. García, S. Saborío, D. Elizondo, J. C. Mercado, K. Gonzalez, C. Cerpas, and A. Nuñez. 2018. Comparison of four serological methods and two reverse transcription-PCR assays for diagnosis and surveillance of Zika virus infection. *Journal of clinical microbiology* 56:
68. Stettler, K., M. Beltramello, D. A. Espinosa, V. Graham, A. Cassotta, S. Bianchi, F. Vanzetta, A. Minola, S. Jaconi, F. Mele, M. Foglierini, M. Pedotti, L. Simonelli, S. Dowall, B. Atkinson, E. Percivalle, C. P. Simmons, L. Varani, J. Blum, F. Baldanti, E. Camerini, R. Hewson, E. Harris, A. Lanzavecchia, F. Sallusto, and D. Corti. 2016. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. *Science* 353: 823-826.

ACKNOWLEDGEMENTS

General: We thank the Veterinary Services, Colony Management, Scientific Protocol Implementation, and the Pathology Services staff at the Wisconsin National Primate Research Center (WNPRC) for their contributions to this study. We thank Brandy Russell for providing virus isolates. The following reagent was obtained through BEI Resources, NIAID, NIH: Dengue Virus Type 2, DENV-2/US/BID-V594/2006, NR-43280.

Funding: This work was supported by 5 R01AI132563-04 from the National Institute of Allergy and Infectious Disease and 5 P51OD011106-59 from the Office of the Director, NIH to the Wisconsin National Primate Research Center. Chelsea M. Crooks was supported by T32 AI007414 from the National Institute of Allergy and Infectious Disease.

Author contributions:

C.M.C. contributed conceptualization, data curation, formal analysis, investigation, methodology, project administration, visualization, validation, writing – original draft, writing – review and editing

A.M.W. contributed data curation, investigation, validation, writing – review and editing

S.L.R. contributed data curation, investigation, validation, writing – review and editing

M.I.B. contributed data curation, investigation, validation, writing – review and editing

A.S.J. contributed investigation, writing – review and editing

M.E.M. contributed data curation, investigation, project administration, validation, writing – review and editing

H.A.S. contributed data curation, formal analysis, investigation, methodology, validation, writing – review and editing

A.M. contributed investigation, methodology, validation, writing – review and editing

M.K.F. contributed investigation, methodology, validation, writing – review and editing

J.M.H. contributed investigation, project administration, writing – review and editing

J.C.E. contributed formal investigation, methodology, software, visualization, writing – review and editing

A.M.M. contributed data curation, investigation, project administration, writing – review and editing

E.R. contributed study data curation, investigation, project administration, writing – review and editing

K.M.B. contributed investigation, writing – review and editing

E.A.B. contributed project administration, writing – review and editing

K.Y. contributed data curation, investigation, project administration, writing – review and editing

P.M.S. contributed data curation, investigation, project administration, writing – review and editing

A.P. contributed investigation, writing – review and editing

K.W. contributed investigation, writing – review and editing

K.M.A. formal analysis, investigation, writing – review and editing
T.K.M. contributed data curation, formal analysis, investigation, methodology, writing – review and editing
C.M.N. contributed conceptualization, methodology, writing – review and editing
D.M.D. contributed conceptualization, methodology, project administration, writing – review and editing
N.S-D. contributed investigation, project administration, writing – review and editing
E.P. contributed investigation, project administration, writing – review and editing
L.C.K. contributed methodology, project administration, writing – review and editing
A.B. contributed data curation, methodology, writing – review and editing
E.H. contributed methodology, project administration, writing – review and editing
D.H.O. contributed conceptualization, data curation, funding acquisition, methodology, project administration, resources, software, supervision, writing – review and editing
E.L.M. contributed conceptualization, data curation, funding acquisition, methodology, project administration, resources, supervision, writing – review and editing
T.G.G contributed conceptualization, data curation, funding acquisition, methodology, project administration, resources, supervision, writing – review and editing
T.C.F. contributed conceptualization, data curation, funding acquisition, methodology, project administration, resources, supervision, writing – review and editing
M.T.A contributed conceptualization, data curation, funding acquisition, investigation, methodology, project administration, resources, supervision, writing – review and editing

Competing interests: The authors declare no competing interests.

Data and materials availability: All of the data used for figure generation and statistical analysis in this manuscript can also be found at <https://github.com/cmc0043/impact-of-denv-on-zikv-during-pregnancy-in-macaques>. Primary data that support the findings of this study will be available in the future at the Zika Open Research Portal (<https://openresearch.labkey.com/project/ZEST/>). Data for the DENV-immune infected cohort can be found under study ZIKV-042; data for DENV-naïve and mock-infected cohorts can be found under ZIKV-044. Raw FASTQ reads of the challenge stock of DENV-2/US/BID-V594/2006 are available at the Sequence Read Archive, BioProject accession number PRJNA435432. Raw FASTQ reads of the challenge stock of ZIKV PRVABC59 are available at the Sequence Read Archive, BioProject accession number PRJNA392686. The authors declare that all other data supporting the findings of this study are available within the article and its supplementary information files.

List of Supplementary Material

Fig. S1. PRNT neutralization curves.

Fig. S2. Placental pathology scoring.

Table S1. Maternal and Fetal Tissue and Fluid ZIKV RNA Detection

Table S2. Placental Pathology Scoring System (central section)